Browsing Tag
IMAAVY
4 posts
Is Johnson & Johnson quietly building a new autoimmune franchise around FcRn inhibition?
Johnson & Johnson is expanding nipocalimab into multiple autoimmune indications. Find out if FcRn inhibition is the foundation of its next blockbuster franchise.
Can Johnson & Johnson’s nipocalimab redefine autoimmune treatment by targeting Sjögren’s disease at its root?
Nipocalimab showed major efficacy in Phase 2 Sjögren’s disease trial. Discover how Johnson & Johnson is advancing autoimmune therapies with its FcRn pipeline.
How does nipocalimab compare to efgartigimod and rozanolixizumab? FcRn class battlelines in gMG and beyond
Compare nipocalimab, efgartigimod, and rozanolixizumab on efficacy, safety, dosing, pricing, and market strategy in generalized myasthenia gravis treatment.
Johnson & Johnson posts sustained superiority for IMAAVY in gMG vs rival FcRn blockers in 24-week indirect comparison
New 24-week comparison shows Johnson & Johnson’s IMAAVY outperforms other FcRn blockers in gMG control—see what this means for patients and investors.